Management

VLP is currently managed by the Company’s Board of Directors comprised of CEO Michael Wyrsta, Chairman Gil Evans, co-founder David Milich and directors Yemi Onakunle and Robert Blatt.

Gilbert Evans (Director and Chairman): Mr. Evans comes to VLP with extensive experience in the equipment leasing and financing industry managing loan portfolios up to $25 million. He currently serves as the Chief Credit Officer for Vision Capital Corporation where he’s been tapped to establish a solid credit platform for expansion of the business into the vendor-finance arena.

David Milich, Ph.D. (Director and founder): Dr. Milich is a world-renowned immunologist with extensive experience in hepatitis B virus research. He has published in excess of 150 peer reviewed articles and has 9 issued patents. His expertise in virology and cellular immunology is a highly valuable asset for VLP’s clinical development programs. Dr. Milich is also President and CEO of VRISD. Prior to starting VLP Biotech, Dr. Milich also co-founded Immune Complex Corporation and was involved in that company’s acquisition by EVAX Technologies in December 2000.

Robert Blatt (Director): Mr. Blatt serves as director on the VLP Board. He contributes extensive financial experience to the VLP board including acquisition and credit line negotiations. He is currently the CFO/Controller of Chicken of the Sea, a company with annual gross sales in excess of $400 million.

Michael D. Wyrsta, Ph.D. (Director and CEO): Dr. Wyrsta has been involved in several start-up ventures, most recently serving as a senior member of GRT, Inc., where his duties included development of novel materials and catalysts in the chemical and petroleum industries. He also served as the Chief Technology Officer of SBA Materials where he established strategic partnerships in the solid-state composite material and pharma industries.

Yemi Onakunle, Ph.D., MBA (Director): Dr. Onakunle brings to the VLP Board extensive experience in technology commercialization and business development within the biopharmaceutical industry.

David Whitacre, Ph.D. (Chief Scientific Officer): Dr. Whitacre comes to VLP from the UCSD Moores Cancer Center in La Jolla, California. His recent work includes the construction of chimeric genes and engineering the adenovirus vector for exogenous gene delivery to mammalian cells. Dr. Whitacre is also an Assistant Member at VRISD.

Darrell Peterson, Ph.D. (Founder): Dr. Peterson is a Professor in the Department of Biochemistry at Virginia Commonwealth University in Richmond, Virginia. He received his Ph.D. from the Department of Biology and Genetics at the University of Notre Dame and has enjoyed a distinguished career studying the structure and functions of viral proteins. He is considered an international expert in the expression, isolation and purification of hepatitis core proteins.